Mr Tod Woolf

Executive Director at Technology Ventures Office, Beth Israel Deaconess Medical Center, Harvard University

Speaker

Twenty-five years’ experience as an entrepreneur and leader of Research, Business Development and Technology Transfer. Has led Technology Transfer at the Harvard Teaching Hospital Beth Israel Deaconess Medical Center since 2019. Founded Sequitur, acquired by Invitrogen. Co-founded and took RXi Pharmaceuticals public. Served as Chief Business and Technology Officer at X-Body BioSciences, acquired by Juno. Served as a Technology Licensing Officer at MIT from 2016-19. Co-developed modified mRNA Therapeutics™, STEALTH RNAi™, Self-Delivering RNAi™ and Therapeutic Editing™.